This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Does Bruker (BRKR) Have the Potential to Rally 33% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 33.5% upside potential for Bruker (BRKR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Bruker (BRKR) to Improve Spatial Biology With New Launch
by Zacks Equity Research
Bruker's (BRKR) acquired company, Canopy Biosciences, introduced its next generation of ChipCytometry instrumentation for spatial biology.
Bruker (BRKR), Newomics to Co-Market Joint MnESI-MS Platform
by Zacks Equity Research
The maxis II and timsTOF Pro 2 mass spectrometers from Bruker (BRKR) will be marketed with Newomics's MnESI product line.
Here's Why You Should Invest In Bruker (BRKR) Stock Now
by Zacks Equity Research
Investors are optimistic about Bruker's (BRKR) better-than-expected revenues and robust segmental performance.
Here's How Much a $1000 Investment in Bruker Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
Wall Street Analysts See a 31% Upside in Bruker (BRKR): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 31.4% in Bruker (BRKR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks Industry Outlook Highlights: Mettler-Toledo International and Bruker
by Zacks Equity Research
Mettler-Toledo International and Bruker are highlighted in this Industry Outlook article.
2 Stocks to Buy on Rising Demand for Scientific Instruments
by Aniruddha Ganguly
The Zacks Instruments - Scientific industry participants like Mettler-Toledo (MTD) and Bruker (BRKR) are gaining from strong life science, pharmaceutical and academic end-market demand as well as rising healthcare spending.
Bruker (BRKR) Q4 Earnings Meet Estimates, Revenues Surpass
by Zacks Equity Research
Robust performance by the BSI and BEST segments drove Bruker's (BRKR) fourth-quarter top line.
Mettler-Toledo (MTD) Q4 Earnings & Sales Beat, Increase Y/Y
by Zacks Equity Research
Mettler-Toledo's (MTD) fourth-quarter 2021 results benefit from robust Laboratory and Industrial segments.
Bruker (BRKR) Meets Q4 Earnings Estimates
by Zacks Equity Research
Bruker (BRKR) delivered earnings and revenue surprises of 0% and 2.83%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Mettler-Toledo (MTD) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Mettler-Toledo (MTD) delivered earnings and revenue surprises of 4.57% and 1.70%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Advanced Energy (AEIS) Q4 Earnings Beat, Revenues Rise Y/Y
by Zacks Equity Research
Advanced Energy's (AEIS) fourth-quarter results reflect strong momentum across semiconductor equipment, data center computing, and industrial and medical markets.
Trimble (TRMB) Q4 Earnings and Revenues Outpace Estimates
by Zacks Equity Research
Trimble (TRMB) reports strong fourth-quarter results driven by solid momentum across buildings & infrastructure, geospatial, and resources & utilities segments.
Vishay (VSH) Q4 Earnings In Line, Revenues Beat Estimates
by Zacks Equity Research
Vishay's (VSH) fourth-quarter results benefit from strong momentum across resistor, capacitor, inductor, MOSFET, diode and opto product lines.
Jack Henry (JKHY) Q2 Earnings & Revenues Beat, Rise Y/Y
by Zacks Equity Research
Jack Henry's (JKHY) second-quarter fiscal 2022 results benefit from strength across Core, Complementary, Corporate and Payments segments.
Carrier (CARR) Q4 Earnings & Sales Beat Estimates, Rise Y/Y
by Zacks Equity Research
Carrier's (CARR) fourth-quarter results benefit from solid momentum across HVAC, transport refrigeration, and Fire and Security.
Teradata (TDC) Q4 Earnings Beat Estimates, Revenues Down Y/Y
by Zacks Equity Research
Teradata's (TDC) fourth-quarter 2021 results benefit from customers' migration to Vantage in the cloud. Yet, a decline in perpetual and consulting revenues remains a headwind.
Bruker (BRKR) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Bruker (BRKR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AMETEK (AME) Q4 Earnings & Sales Beat Estimates, Rise Y/Y
by Zacks Equity Research
AMETEK's (AME) fourth-quarter results reflect solid momentum in the EIG and EMG segments.
FormFactor (FORM) Q4 Earnings Beat, Revenues Increase Y/Y
by Zacks Equity Research
FormFactor's (FORM) fourth-quarter 2021 earnings are driven by strong demand for DRAM, Flash and Systems.
PerkinElmer (PKI) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
PerkinElmer (PKI) delivered earnings and revenue surprises of 19.07% and 9.46%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Hold on to Bruker (BRKR) Stock for Now
by Zacks Equity Research
Investors are optimistic about Bruker's (BRKR) growth in the BioSpin Group and CALID Group.
Is Axcelis Technologies (ACLS) Stock Outpacing Its Computer and Technology Peers This Year?
by Zacks Equity Research
Here is how Axcelis Technologies (ACLS) and Bruker (BRKR) have performed compared to their sector so far this year.
Bruker (BRKR) Introduces JPK NanoWizard V for AFM Research
by Zacks Equity Research
Bruker's (BRKR) newly-introduced JPK NanoWizard V is expected to significantly contribute to life science atomic force microscopy investigations.